Anaes · Anaesthetic adjuncts
Methadone
Also known as Methadone hydrochloride · Long-acting mu agonist with NMDA antagonism
Methadone for the anaesthesia fellowship exams: a synthetic mu agonist with NMDA antagonism, a long and variable half-life that outlasts its analgesic action, QT prolongation, cytochrome P450 interactions, non-linear opioid conversion, and the single intraoperative dose.
Checked against its sources on 23 Oct 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- The analgesic action of methadone lasts 4 to 8 hours but its plasma elimination half-life is 8 to 59 hours; its peak respiratory depressant effects occur later and persist longer than its peak analgesic effects.
- QT prolongation and torsades de pointes have occurred during methadone treatment, more commonly at doses above 200 mg/day.
- The potency of methadone relative to other opioids is non-linear and increases with increasing dose; deaths have occurred in opioid-tolerant patients during conversion.
- Methadone is a long-acting depressant (36 to 48 hours), whereas opioid reversal agents act for one to three hours: monitor until spontaneous respiration is reliably re-established.
Mechanism of action
Methadone hydrochloride is a mu agonist, a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine. Some data also indicate that methadone acts as an antagonist at the NMDA receptor; the contribution of NMDA antagonism to its efficacy is unknown.[6]
Methadone has a unique mechanism of action compared with all other opioids, and for this reason holds a niche role in the management of opioid-induced hyperalgesia and central sensitisation.[1]
Methadone produces respiratory depression by direct action on brain stem respiratory centres, reducing their responsiveness to increases in carbon dioxide tension and to electrical stimulation.[6]
References8ShowHide
- [1]Kreutzwiser D, Tawfic QA Methadone for Pain Management: A Pharmacotherapeutic Review CNS Drugs, 2020.PMID 32564328
- [2]Murphy GS, Szokol JW, Avram MJ, et al. Intraoperative Methadone for the Prevention of Postoperative Pain: A Randomized, Double-blinded Clinical Trial in Cardiac Surgical Patients Anesthesiology, 2015.PMID 25837528
- [3]Murphy GS, Avram MJ, Greenberg SB, et al. Postoperative Pain and Analgesic Requirements in the First Year after Intraoperative Methadone for Complex Spine and Cardiac Surgery Anesthesiology, 2020.PMID 31939849
- [4]El Sherbini A, Liblik K, Lee J, et al. Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature Trends Cardiovasc Med, 2024.PMID 37015297
- [5]Mercadante S, Caraceni A Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review Palliat Med, 2011.PMID 21708857
- [6]Mylan Institutional LLC METHADONE HYDROCHLORIDE injection, solution — prescribing information. DailyMed, 2026.Source
- [7]VistaPharm, LLC METHADONE HYDROCHLORIDE tablet — prescribing information. DailyMed, 2026.Source
- [8]Nunez-Rodriguez E, et al. Evaluating respiratory depression after methadone administration in surgical patients: protocol for a systematic review and meta-analysis BMJ Open, 2025.PMID 40447426